Skip to main content
EJNMMI Research

Table 1 Patient characteristics

From: Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

All patients (n)

6

 Male

1

 Female

5

Age (years)

 Average

65

 Range

57–75

EGFR mutation (n)

 Exon 18 G719X

2

 Exon 19 Del E746-A750

1

 Exon 21 L585R

3

Treatment (n)

 Erlotinib

2

 Gefitinib

4

Back to article page